Compare Eli Lilly And Co (LLY) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Prospect Capital Corporation — how do they compare? Eli Lilly And Co trades at $1,215.94 (market cap $1.08T), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: Eli Lilly And Co is far larger — about 947.4× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (21.93%). Which is the better fit depends on your goals.
| LLY | PSEC | |
|---|---|---|
Market Cap | $1.08T | $1.14B |
Sector | Health | Financials |
52-Week High | $1.24K | $3.05 |
52-Week Low | $639.43 | $2.11 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | 21.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Prospect Capital Corporation (PSEC) trades at $2.285, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows mixed fundamentals with a low P/B ratio of 0.39 but negative revenue and net income margins. Recent earnings have consistently beaten expectations, and the company maintains regular dividend payments of $0.04 per share. Analyst sentiment is divided with 25% buy ratings, 55% hold, and 20% sell recommendations.
PSEC presents a high-risk, high-yield opportunity trading at a significant discount to book value. The investment case hinges on the company's ability to stabilize revenue and return to profitability while maintaining its dividend distribution. Key risks include persistent negative revenue trends, high leverage costs, and market skepticism about portfolio quality despite recent successful exits like the Valley Electric sale generating 4.8x returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
